BILLIE GEISE: Open Payments
NPI 1144692054 · CAMBRIDGE CITY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 37 payments from 13 companies in 2025. Trend: 2023 $305 · 2024 $512 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $197 |
| Amgen Inc. | 4 | $64 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Novo Nordisk Inc | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $24 |
| PFIZER INC. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 2 | $20 |
Products named: VRAYLAR, UBRELVY, OTEZLA, CAPLYTA, QULIPTA, Auvelity, AIRSUPRA, Rybelsus.
Industry payments across IN — which companies pay providers there.
